{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:13:41Z","timestamp":1777950821996,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["Grant No. 3\/2\/3\/73\/2022-NCD-III"],"award-info":[{"award-number":["Grant No. 3\/2\/3\/73\/2022-NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12010-026-05618-9","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:52:40Z","timestamp":1772873560000},"page":"3929-3953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Lapatinib and Tucatinib as Dual Inhibitors of Bcl-2 and TYMS in Breast Cancer: Insights from Transcriptomic, Computational and Cellular Assays"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-482X","authenticated-orcid":false,"given":"Mehreen","family":"Aftab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shagufta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Sisodiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asiya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Showket","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"4785","key":"5618_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/ neu oncogene. Science, 235(4785), 177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106","journal-title":"Science"},{"issue":"7","key":"5618_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., M\u00fcller, V., Braga, S., Duhoux, F. P., Greil, R., \u2026 Winer, E. P. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. The New England Journal of Medicine, 382(7), 597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"5618_CR3","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., Skarlos, D., Campone, M., Davidson, N., Berger, M., Oliva, C., Rubin, S. D., Stein, S., & Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England Journal of Medicine, 355(26), 2733\u20132743. https:\/\/doi.org\/10.1056\/NEJMoa064320","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"5618_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","volume":"17","author":"BN Rexer","year":"2012","unstructured":"Rexer, B. N., & Arteaga, C. L. (2012). Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications. Critical Reviews in Oncogenesis, 17(1), 1\u201316. https:\/\/doi.org\/10.1615\/CritRevOncog.v17.i1.20","journal-title":"Critical Reviews in Oncogenesis"},{"issue":"23","key":"5618_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41388-023-02694-7","volume":"42","author":"MV Guijarro","year":"2023","unstructured":"Guijarro, M. V., Nawab, A., Dib, P., Burkett, S., Luo, X., Feely, M., Nasri, E., Seifert, R. P., Kaye, F. J., & Zajac-Kaye, M. (2023). TYMS promotes genomic instability and tumor progression in Ink4a\/Arf null background. Oncogene, 42(23), 1926\u20131939. https:\/\/doi.org\/10.1038\/s41388-023-02694-7","journal-title":"Oncogene"},{"issue":"6","key":"5618_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13061292","volume":"13","author":"S Hafezi","year":"2021","unstructured":"Hafezi, S., & Rahmani, M. (2021). Targeting BCL-2 in cancer: Advances, challenges, and perspectives. Cancers, 13(6), 1\u201313. https:\/\/doi.org\/10.3390\/CANCERS13061292","journal-title":"Cancers"},{"issue":"1\u20132","key":"5618_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023). BCL-2 protein family: Attractive targets for cancer therapy. Apoptosis, 28(1\u20132), 20\u201338. https:\/\/doi.org\/10.1007\/s10495-022-01780-7","journal-title":"Apoptosis"},{"issue":"9","key":"5618_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory, S., & Adams, J. M. (2002). The Bcl-2 family: Regulators of the cellular life-or-death switch. Nature Reviews Cancer, 2(9), 647\u2013656. https:\/\/doi.org\/10.1038\/nrc883","journal-title":"Nature Reviews Cancer"},{"issue":"5381","key":"5618_CR9","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","volume":"281","author":"JM Adams","year":"1998","unstructured":"Adams, J. M., & Cory, S. (1998). The Bcl-2 protein family: Arbiters of cell survival. Science, 281(5381), 1322\u20131326. https:\/\/doi.org\/10.1126\/science.281.5381.1322","journal-title":"Science"},{"issue":"1","key":"5618_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-153","volume":"8","author":"GM Callagy","year":"2008","unstructured":"Callagy, G. M., Webber, M. J., Pharoah, P. D., & Caldas, C. (2008). Meta-analysis confirms BCL-2 is an independent prognostic marker in breast cancer. BMC Cancer, 8(1), Article 153. https:\/\/doi.org\/10.1186\/1471-2407-8-153","journal-title":"BMC Cancer"},{"issue":"8","key":"5618_CR11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1158\/1078-0432.CCR-05-2719","volume":"12","author":"GM Callagy","year":"2006","unstructured":"Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., & Caldas, C. (2006). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index. Clinical Cancer Research, 12(8), 2468\u20132475. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2719","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"5618_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2174\/092986709787581905","volume":"16","author":"P Wu","year":"2009","unstructured":"Wu, P., Liu, T., & Hu, Y. (2009). PI3K inhibitors for cancer therapy: What has been achieved so far? Current Medicinal Chemistry, 16(8), 916\u2013930. https:\/\/doi.org\/10.2174\/092986709787581905","journal-title":"Current Medicinal Chemistry"},{"issue":"1","key":"5618_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1146\/annurev.bi.64.070195.003445","volume":"64","author":"CW Carreras","year":"1995","unstructured":"Carreras, C. W., & Santi, D. V. (1995). The catalytic mechanism and structure of thymidylate synthase. Annual Review of Biochemistry, 64(1), 721\u2013762. https:\/\/doi.org\/10.1146\/annurev.bi.64.070195.003445","journal-title":"Annual Review of Biochemistry"},{"issue":"7","key":"5618_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05963-1","volume":"14","author":"E Valentini","year":"2023","unstructured":"Valentini, E., Di Martile, M., Brignone, M., Di Caprio, M., Manni, I., Chiappa, M., & Del Bufalo, D. (2023). Bcl-2 family inhibitors sensitize human cancer models to therapy. Cell Death & Disease, 14(7), Article 441. https:\/\/doi.org\/10.1038\/s41419-023-05963-1","journal-title":"Cell Death & Disease"},{"issue":"3","key":"5618_CR15","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1007\/s12013-024-01388-5","volume":"82","author":"L Wang","year":"2024","unstructured":"Wang, L., Wu, Z., Wang, Y., Chen, C., Li, Y., Dong, H., & Wang, Z. (2024). TYMS knockdown suppresses cells proliferation, promotes ferroptosis via inhibits PI3K\/Akt\/mTOR signaling pathway activation in triple negative breast cancer. Cell Biochemistry and Biophysics, 82(3), 2717\u20132726. https:\/\/doi.org\/10.1007\/s12013-024-01388-5","journal-title":"Cell Biochemistry and Biophysics"},{"key":"5618_CR16","doi-asserted-by":"publisher","unstructured":"Li, S., Zhao, J., Lv, L., & Dong, D. (2021). Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma. Frontiers in Oncology, 11. https:\/\/doi.org\/10.3389\/fonc.2021.762821","DOI":"10.3389\/fonc.2021.762821"},{"key":"5618_CR17","unstructured":"Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer - PubMed. (n.d.). Retrieved July 17, 2024, from https:\/\/pubmed.ncbi.nlm.nih.gov\/31551176\/"},{"key":"5618_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.08.006","author":"Y Chao","year":"2018","unstructured":"Chao, Y., & Anders, C. K. (2018). TYMS gene polymorphisms in breast cancer patients receiving 5\u2013fluorouracil-based chemotherapy. Clinical Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2017.08.006","journal-title":"Clinical Breast Cancer"},{"issue":"7","key":"5618_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., & Winer, E. P. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. The New England Journal of Medicine, 382(7), 597\u2013609.","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"5618_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/S12094-022-03070-9","volume":"25","author":"I Ploumaki","year":"2023","unstructured":"Ploumaki, I., Triantafyllou, E., Koumprentziotis, I. A., Karampinos, K., Drougkas, K., Karavolias, I., & Kotteas, E. A. (2023). Bcl-2 pathway inhibition in solid tumors: A review of clinical trials. Clinical & Translational Oncology, 25(6), Article 1554. https:\/\/doi.org\/10.1007\/S12094-022-03070-9","journal-title":"Clinical & Translational Oncology"},{"issue":"1","key":"5618_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/CDD.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero, J., & Letai, A. (2018). Why do BCL-2 inhibitorswork and where should we use them in the clinic? Cell Death and Differentiation, 25(1), 56\u201364. https:\/\/doi.org\/10.1038\/CDD.2017.183","journal-title":"Cell Death and Differentiation"},{"issue":"10","key":"5618_CR22","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.3107","volume":"6","author":"C Burdelski","year":"2015","unstructured":"Burdelski, C., Strauss, C., Tsourlakis, M. C., Kluth, M., Hube-Magg, C., Melling, N., Lebok, P., Minner, S., Koop, C., Graefen, M., Heinzer, H., Wittmer, C., Krech, T., Sauter, G., Wilczak, W., Simon, R., Schlomm, T., & Steurer, S. (2015). Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumour features and early PSA recurrence in prostate cancer. Oncotarget, 6(10), Article 8377. https:\/\/doi.org\/10.18632\/ONCOTARGET.3107","journal-title":"Oncotarget"},{"key":"5618_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/BCTT.S29996","volume":"4","author":"SA Hurvitz","year":"2012","unstructured":"Hurvitz, S. A., & Kakkar, R. (2012). Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 4, 35\u201351. https:\/\/doi.org\/10.2147\/BCTT.S29996","journal-title":"Breast Cancer: Targets and Therapy"},{"key":"5618_CR24","doi-asserted-by":"publisher","unstructured":"Wang, X., Wang, L., Yu, Q., Liu, Z., Li, C., Wang, F., & Yu, Z. (2021). The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China. Technology in Cancer Research and Treatment, 20. https:\/\/doi.org\/10.1177\/15330338211037812\/ASSET\/IMAGES\/LARGE\/10.1177_15330338211037812-FIG4.JPEG","DOI":"10.1177\/15330338211037812\/ASSET\/IMAGES\/LARGE\/10.1177_15330338211037812-FIG4.JPEG"},{"issue":"18","key":"5618_CR25","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.7150\/jca.88446","volume":"14","author":"W Shu","year":"2023","unstructured":"Shu, W., Wang, J. Z., Zhu, X., Wang, K., Cherepanoff, S., Conway, R. M., & Zhou, F. (2023). Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells. Journal of Cancer, 14(18), 3477\u20133495. https:\/\/doi.org\/10.7150\/jca.88446","journal-title":"Journal of Cancer"},{"issue":"1","key":"5618_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1186\/s12885-018-4852-1","volume":"18","author":"AJ Eustace","year":"2018","unstructured":"Eustace, A. J., Conlon, N. T., McDermott, M. S. J., Browne, B. C., O\u2019Leary, P., Holmes, F. A., & Crown, J. (2018). Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer, 18(1), 965. https:\/\/doi.org\/10.1186\/s12885-018-4852-1","journal-title":"BMC Cancer"},{"issue":"9","key":"5618_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1634\/THEONCOLOGIST.2009-0181","volume":"15","author":"D Cameron","year":"2010","unstructured":"Cameron, D., Casey, M., Oliva, C., Newstat, B., Imwalle, B., & Geyer, C. E. (2010). Lapatinib Plus Capecitabine in Women with HER-2\u2013Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial. The Oncologist, 15(9), 924\u2013934. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2009-0181","journal-title":"The Oncologist"},{"issue":"9","key":"5618_CR28","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/2767-9764.CRC-23-0302","volume":"3","author":"D Olson","year":"2023","unstructured":"Olson, D., Taylor, J., Willis, K., Hensley, K., Allred, S., Zaval, M., & Kulukian, A. (2023). HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer. Cancer Research Communications, 3(9), 1927\u20131939. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0302","journal-title":"Cancer Research Communications"},{"issue":"9","key":"5618_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","volume":"4","author":"VF Borges","year":"2018","unstructured":"Borges, V. F., Ferrario, C., Aucoin, N., Falkson, C., Khan, Q., Krop, I., & Hamilton, E. (2018). Tucatinib combined with Ado-Trastuzumab Emtansine in advanced ERBB2\/HER2 -positive metastatic breast cancer. JAMA Oncology, 4(9), 1214. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1812","journal-title":"JAMA Oncology"},{"key":"5618_CR30","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9068","author":"A Matsumoto","year":"2018","unstructured":"Matsumoto, A., Hayashida, T., Takahashi, M., Jinno, H., & Kitagawa, Y. (2018). Antitumour effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer. Molecular Medicine Reports. https:\/\/doi.org\/10.3892\/mmr.2018.9068","journal-title":"Molecular Medicine Reports"},{"key":"5618_CR31","doi-asserted-by":"publisher","unstructured":"O\u2019Brien, B. J., Murthy, R. K., Berry, D. A., Singareeka Raghavendra, A., Gule-Monroe, M., Johnson, J. M., \u2026 Stringer-Reasor, E. M. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Journal of Clinical Oncology, 42(16_suppl), 2018\u20132018. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2018","DOI":"10.1200\/JCO.2024.42.16_suppl.2018"},{"issue":"7","key":"5618_CR32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/JNCI\/DJAD072","volume":"115","author":"R Li","year":"2023","unstructured":"Li, R., Sant, S., Brown, E., Caramia, F., Nikolic, B., Clarke, K., & Loi, S. (2023). Tucatinib promotes immune activation and synergizes with programmed cell death\u20131 and programmed cell death\u2013ligand 1 inhibition in HER2-positive breast cancer. JNCI Journal of the National Cancer Institute, 115(7), 805. https:\/\/doi.org\/10.1093\/JNCI\/DJAD072","journal-title":"JNCI Journal of the National Cancer Institute"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05618-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:17:22Z","timestamp":1777882642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-026-05618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5618"],"URL":"https:\/\/doi.org\/10.1007\/s12010-026-05618-9","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"4 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study as it used publicly available, anonymized data and did not involve human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}